Evaluation of Immunogenicity and Safety of Combined Immunization of COVAX (Produced in Wuhan) and PPV23 / IIV4

NCT05079152 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

1404

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza, Human
Pneumonia, Pneumococcal
COVID-19 Pneumonia

Interventions

BIOLOGICAL: COVAX+PPV23;COVAX+IIV4
BIOLOGICAL: COVAX only (1st and 2nd dose)
BIOLOGICAL: PPV23 for the 1st dose and IIV4 for the 2nd dose

Sponsor

China National Biotec Group Company Limited

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]